Analyst Ranking
Bottom 26%
#3866 out of 5150 analysts
Average Return
-0.03%
Win Rate
40%35 out of 88
Risk vs Reward
Poor
Good

Paul Matteis's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Alto Neuroscience IncANRO
+213.47%$4.53$14.20
2024-11-12 -
2025-11-12
Strong Buy
Sionna Therapeutics IncSION
+188.99%$14.80$42.77
2025-03-03 -
2025-12-12
Strong Buy
Rhythm Pharmaceuticals IncRYTM
+114.39%$52.97$113.56
2025-03-04 -
2025-12-12
Strong Buy
Dyne Therapeutics IncDYN
+95.63%$9.85$19.27
2025-07-30 -
2025-12-12
Strong Buy
Rhythm Pharmaceuticals IncRYTM
+83.52%$61.88$113.56
2025-05-28 -
2025-12-12
Strong Buy

Paul Matteis's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Uniqure NvQURE
3Strong Buy$40.00+105.02%Maintains
3 days ago
Neurocrine Biosciences IncNBIX
8Strong Buy$188.00+23.04%Maintains
3 days ago
Lb Pharmaceuticals IncLBRX
2Strong Buy$35.00+83.01%Maintains
3 days ago
Dyne Therapeutics IncDYN
5Strong Buy$39.00+102.39%Maintains
3 days ago
Alnylam Pharmaceuticals IncALNY
10Strong Buy$508.00+27.78%Maintains
3 days ago
Acadia Pharmaceuticals IncACAD
6Hold$25.00-7.92%Maintains
3 days ago
Maplight Therapeutics IncMPLT
1Strong Buy$28.00+35.27%Initiates Coverage On
23 days ago
Neumora Therapeutics IncNMRA
3Hold$3.00+43.54%Maintains
a month ago
Biomarin Pharmaceutical IncBMRN
11Hold$61.00+14.43%Downgrades
a month ago
Biogen IncBIIB
7Strong Buy$202.00+16.03%Upgrades
a month ago
Vertex Pharmaceuticals IncVRTX
15Hold$445.00-1.56%Maintains
a month ago
Ionis Pharmaceuticals IncIONS
5Hold$67.00-17.10%Maintains
2 months ago
Pepgen IncPEPG
3Strong Buy$12.00+112.01%Maintains
3 months ago
Rhythm Pharmaceuticals IncRYTM
2Strong Buy$94.00-17.22%Maintains
6 months ago
Vigil Neuroscience IncVIGL
2Hold$8.00-0.62%Downgrades
7 months ago
Sionna Therapeutics IncSION
1Strong Buy$32.00-25.18%Initiates Coverage On
9 months ago
Gh Research PLCGHRS
2Strong Buy$32.00+145.49%Maintains
10 months ago
Compass Pathways PLCCMPS
1Strong Buy$11.00+63.20%Initiates Coverage On
10 months ago
Sage Therapeutics IncSAGE
5Hold$6.00-30.88%Maintains
a year ago
Denali Therapeutics IncDNLI
3Strong Buy$37.00+105.78%Upgrades
a year ago
Alector IncALEC
5Hold$4.00+168.46%Downgrades
a year ago
Alto Neuroscience IncANRO
3Strong Buy$10.00N/AMaintains
a year ago
Neurogene IncNGNE
2Strong Buy$60.00N/AMaintains
a year ago
Alkermes PLCALKS
5Strong Buy$36.00N/AUpgrades
a year ago
Rapport Therapeutics IncRAPP
1Strong Buy$35.00N/AInitiates Coverage On
a year ago
Contineum Therapeutics IncCTNM
1Strong Buy$29.00N/AInitiates Coverage On
2 years ago
Lexeo Therapeutics IncLXEO
1Strong Buy$20.00N/AInitiates Coverage On
2 years ago
Vistagen Therapeutics IncVTGN
1Strong Buy$12.00N/AInitiates Coverage On
2 years ago
Karuna Therapeutics IncKRTX
3Strong Buy$295.00N/AMaintains
3 years ago
Cerevel Therapeutics Holdings IncCERE
2Strong Buy$54.00N/AMaintains
3 years ago
Athira Pharma IncATHA
2Hold$50.00N/ADowngrades
3 years ago
Kalvista Pharmaceuticals IncKALV
1Strong Buy$32.00N/AMaintains
4 years ago
Climb Bio IncCLYM
1Strong Buy$35.00N/AInitiates Coverage On
4 years ago
Acumen Pharmaceuticals IncABOS
1Strong Buy$27.00N/AInitiates Coverage On
4 years ago
Prevail Therapeutics IncPRVL
1Strong Buy$23.00N/AInitiates Coverage On
5 years ago
Gw Pharmaceuticals PLCGWPH
4Hold$140.00N/ADowngrades
5 years ago
Avadel Pharmaceuticals PLCAVDL
1Strong Buy$14.00N/AInitiates Coverage On
6 years ago
Zogenix IncZGNX
3Buy$60.00N/AInitiates Coverage On
7 years ago
Acorda Therapeutics IncACORQ
1Hold$2,280.00N/AMaintains
7 years ago
Akcea Therapeutics IncAKCA
2Hold$31.00N/AMaintains
7 years ago
Obseva SaOBSVF
1Buy$18.00N/AMaintains
8 years ago
Wave Life Sciences LtdWVE
1Buy$64.00N/AMaintains
8 years ago
Cidara Therapeutics IncCDTX
1Buy$340.00N/AInitiates Coverage On
9 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.